FDG (Fluorodeoxyglucose) Findings After COVID-19 Vaccination (fdg)

Kocaeli University

Status: Completed

Conditions: Oncology; Vaccine Reaction

Treatments: Biological: Pfizer/biontech mRNA vaccine; Diagnostic Test: F-18 FDG PET/CT imaging

Study type: Observational

Funder types: Other

Identifiers

NCT05270967

GOKAEK-2021/14.18

Details and patient eligibility

About

It is important to evaluate the vaccine-related metabolic changes on FDG PET/CT to avoid confusing results. The investigators aimed to assess the frequency and intensity of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine (BNT162b2-Pfizer/BioNTech) and to analyze possible factors affecting these changes.

Enrollment: 129 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients referred for post-vaccination FDG PET/CT imaging

Exclusion criteria

• Disseminated metastatic disease, ipsilateral breast cancer or lymphoma that was likely to involve axilla, and patients who had ipsilateral intense axillary uptake or thyroiditis on their prior imaging, were exclusion criteria